Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies

NCT04464200 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04464200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 6, 2020
Completion date
July 31, 2027
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt's lymphoma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, indolent non-hodgkin lymphoma, marginal zone lymphoma, primary cns lymphoma, primary mediastinal large b cell lymphoma, transformed follicular lymphoma to diffuse large b cell lymphoma, waldenstrom macroglobulinemia